Company Analysis Global Health Limited
1. Summary
Advantages
- The company's current efficiency (ROE=17.93%) is higher than the sector average (ROE=3.58%)
Disadvantages
- Price (1187.45 βΉ) is higher than fair price (408.64 βΉ)
- Dividends (0%) are below the sector average (0.6581%).
- The stock's return over the last year (10.53%) is lower than the sector average (16.88%).
- Current debt level 9.74% has increased over 5 years from 0%.
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
Global Health Limited | Healthcare | Index | |
---|---|---|---|
7 days | -0.9% | 2.3% | -0.4% |
90 days | -6.4% | 7.6% | 2.8% |
1 year | 10.5% | 16.9% | 0.2% |
MEDANTA vs Sector: Global Health Limited has significantly underperformed the "Healthcare" sector by -6.36% over the past year.
MEDANTA vs Market: Global Health Limited has outperformed the market by 10.37% over the past year.
Stable price: MEDANTA is not significantly more volatile than the rest of the market on "Bombay Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: MEDANTA with weekly volatility of 0.2024% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (1187.45 βΉ) is higher than the fair price (408.64 βΉ).
Price is higher than fair: The current price (1187.45 βΉ) is 65.6% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (72.42) is higher than that of the sector as a whole (56.1).
P/E vs Market: The company's P/E (72.42) is higher than that of the market as a whole (44.6).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (11.92) is higher than that of the sector as a whole (8.11).
P/BV vs Market: The company's P/BV (11.92) is higher than that of the market as a whole (5.33).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (10.69) is lower than that of the sector as a whole (17.81).
P/S vs Market: The company's P/S indicator (10.69) is higher than that of the market as a whole (8.99).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (0) is lower than that of the sector as a whole (4.22).
EV/Ebitda vs Market: The company's EV/Ebitda (0) is lower than that of the market as a whole (15.13).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by 0% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (0%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-17.15%).
5.4. ROE
ROE vs Sector: The company's ROE (17.93%) is higher than that of the sector as a whole (3.58%).
ROE vs Market: The company's ROE (17.93%) is higher than that of the market as a whole (-1.52%).
5.5. ROA
ROA vs Sector: The company's ROA (11.36%) is higher than that of the sector as a whole (3.38%).
ROA vs Market: The company's ROA (11.36%) is higher than that of the market as a whole (7.42%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (13.38%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (13.44%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.6581%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription